Filter
589
Text search:
variant
Featured
71
85
Language
Document type
176
145
142
35
28
27
17
6
6
5
1
1
Countries
28
26
24
21
14
13
12
12
11
10
9
8
7
7
7
7
7
7
6
6
6
5
5
5
5
5
4
4
4
4
4
4
4
3
3
3
3
3
3
2
2
2
2
2
2
2
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
1
Authors & Publishers
Publication Years
Category
239
37
20
19
13
12
6
1
Toolboxes
206
40
19
14
13
12
12
12
12
11
10
10
10
9
9
8
7
6
6
5
5
3
2
1
1
1
Le présent guide qui comprend une liste consensuelle de quarante-cinq (45) maladies,
affections et évènements prioritaires est structuré en une partie introductive comportant des définitions et généralités et de neuf (09) sections.
Les 9 sections sont :
i) identifier les cas de maladies,
...
Cette évaluation a trois principaux objectifs :
1 - Evaluer la qualité des données collectées par le système LP depuis septembre 2010 à septembre 2012.
2 - En fonction de la qualité de ces données, appuyer l’équipe terrain, basée principalement à Diapaga, dans l’analyse statistique
...
10 December 2020
These WHO interim recommendations on the use of the Pfizer – BioNTech BNT162b2 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
fir
...
8 January 2021
Sequencing enabled the world to rapidly identify SARS-CoV-2 and develop diagnostic tests and other tools for outbreak management. Continued genome sequencing supports the monitoring of the disease’s spread and evolution of the virus. Accelerated integration of genome sequencing int
...
nterim guidance, first issued 25 January 2021, updated 15 June 2021, updated 19 November 2021, updated 23 February 2022, updated 18 August 2022
Coronavirus – wir informieren in mehreren Sprachen
Die Informationen werden laufend erweitert und aktualisiert.
WHO has a unique combination of technical public health and scientific expertise, and a global operational footprint, with field offices in more than 150 countries. In 2020, this global, technical, and operational reach meant WHO was able to support countries around the world in every aspect of COVI
...
Manufacturers:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
Efficacy shown in clinical trials in participants who received the full series of vaccine (2 doses) ir
...
Interim Guidance October 2022. This addendum addresses some of the methodological aspects of VE evaluations that have been learned during the past year, as well as those that have become relevant in the current epidemiological setting of the COVID-19 pandemic. For some of the COVID-19 vaccine method
...
These are standing orders for eligible nurses and healthcare professionals to administer the Moderna COVID-19 vaccine to persons 18 years of age and older
Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac
These WHO interim recommendations for use of the Sinovac-CoronaVac were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been updat
...
10 May 2021. Manufactureres:
SK Bioscience Co. Ltd. [COVID-19 Vaccine (ChAdOx1-S [recombinant])]
Serum Institute of India Pvt. Ltd. [COVISHIELD™, ChAdOx1 nCoV-19 Corona Virus Vaccine (Recombinant)]
The ChAdOx1-S/nCoV-19 [recombinant] vaccine is a replication-deficient adenoviral vecto
...
Bisher hat die STIKO empfohlen, dass alle im Ausland mit einem nicht in der EU zugelassenen Impfstoff geimpften Personen eine erneute Impfserie mit einem in der EU zugelassenen Impfstoff erhalten sollen. Ziel der im Epidemiologischen Bulletin 13/2022 veröffentlichten aktualisierten COVID-19-Impfemp
...
12 May 2021. This third survey in the series shows that the COVID-19 pandemic continues to impact societies, not only in terms of health, but also social and economic conditions and day-to-day life
